Trial Profile
A phase I dose escalation study of Upamostat in Chinese patients with solid tumour
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 21 Mar 2019 According to Heidelberg Pharma AG media release, the IND application submitted by Link Health for conducting clinical trials with MESUPRON(R) was approved.
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 17 Jan 2016 New trial record